Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis—An Invitation to Further Investigation into Polypharmacy Reduction

Aim. Animal and human study evidence supports the hypothesis that flaxseed lignan complex (FLC) at a dose of 600 mg secoisolariciresinol diglucoside (SDG)/day for three months would combat hyperglycaemia, dyslipidemia, blood pressure, central obesity, prothrombotic state, inflammation, and low densi...

Descripción completa

Detalles Bibliográficos
Autores principales: Barre, D. E., Mizier-Barre, K. A., Stelmach, E., Hobson, J., Griscti, O., Rudiuk, A., Muthuthevar, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471460/
https://www.ncbi.nlm.nih.gov/pubmed/23094144
http://dx.doi.org/10.1155/2012/585170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471460/
https://www.ncbi.nlm.nih.gov/pubmed/23094144
http://dx.doi.org/10.1155/2012/585170

Ejemplares similares